Rushton, MJohnson, CDent, S2019-03-292019-03-2920171198-0052https://doi.org/10.20381/ruor-23258http://hdl.handle.net/10393/39008Trastuzumab has improved survival for women with her2-positive breast cancer, but its use is associated with an increased risk of cardiotoxicity. With increased survivorship, the long-term effects of cancer treatment are an important consideration for clinicians and patients. We reviewed the current literature on predicting trastuzumab-related cardiotoxicity and tested a clinical risk score (crs) in a real-world breast cancer population to assess its utility in predicting permanent cardiotoxicity.enBreast cancercardiotoxicityheart failuretrastuzumabArticle10.3747/co.24.3349